Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Timp2 loss-of-function mutation and TIMP2 treatment in a murine model of NSCLC: Modulation of immunosuppression and oncogenic signaling

Translational Oncology(2025)10.1016/j.tranon.2025.102309Source: DataRank Database

Timp2 loss-of-function mutation and TIMP2 treatment in a murine model of NSCLC: Modulation of immunosuppression and oncogenic signaling is a research paper published in Translational Oncology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.00)OA: goldTopics (23)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Sarvesh Kumar ORCID,Tej Pratap Singh ORCID,Yueqin Liu,Sandra Jensen,Anandã Chowdhury ORCID

Live enrichment

PubMed:39904284 PMC:PMC11846589 OpenAlex:https://openalex.org/W4407084533

National Cancer Institute

Grant: ZIA BC011204

National Cancer Institute

Grant: ZIA SC 009179

National Institutes of Health

Grant: 129/ReJ

National Institutes of Health

Grant: 1Z01SC009179-09

NOVEL METALLOPROTEINASE INHIBITORS--ROLE IN TUMOR INVASION AND METASTASIS

National Institutes of Health

Grant: 1ZIABC011204-03

Preclinical development of AlaTIMP-2 as an cancer therapeutic

National Cancer Institute

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.tranon.2025.102309

publisherhttps://doi.org/10.1016/j.tranon.2025.102309

publisherhttps://api.elsevier.com/content/article/PII:S1936523325000403?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523325000403?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39904284

Fields of Study

Ubiquitin and proteasome pathwaysCytokine Signaling Pathways and Interactionsinterferon and immune responses03 medical and health sciences0302 clinical medicine

Keywords

ImmunosuppressionFunction (biology)MutationCancer researchModulation (music)MedicineBiologyImmunologyGeneticsGeneLung cancerTherapyLewis lung carcinomaTimp2Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ArticleOriginal Research

Sustainable Development Goals

SDG 0: Good health and well-being